Milos Grujic: First RCT comparing ENRT vs MDT in Oligorecurrent Nodal
Milos Grujic, Radiation Oncologist at the University Clinical Center Kragujevac, shared an article on X:
“New in The Lancet Oncology and at ESTRO25 PEACE V–STORM: First RCT comparing ENRT vs MDT in oligorecurrent nodal.
ENRT and ADT improved:
- Metastasis-free survival (76% vs 63%).
- Biochemical relapse-free survival (57% vs 41%).
- ADT-free survival (77% vs 60%).
Potential new standard?”
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial.
Authors: Piet Ost, Prof Shankar Siva, Sigmund Brabrand, Piet Dirix, Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-Iturriaga, Wouter Everaerts, Mohamed Shelan, Prof Antonio Conde-Moreno, Fernando López Ca mpos, Alexandros Papachristofilou, Prof Matthias Guckenberger, Prof Marta Scorsetti, Almudena Zapatero, Ana-Elena Villafranca Iturre, Clara Eito, Prof Felipe Couñago, Paolo Muto, Wim Duthoy, Nicolas Mach, Valérie Fonteyne, Daniel Moon, Kristian Thon, Carole Mercier, Vérane Achard, Karin Stellamans, Prof Els Goetghebeur, Dries Reynders, Thomas Zilli.
You can read the Full Article on Journal of The Lancet Oncology.
More posts featuring Milos Grujic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023